Key Findings from Adaptimmune's IGNYTE-ESO Trial Interim Analysis
Monday, 3 June 2024, 13:12
Adaptimmune to Present Data from Pivotal IGNYTE-ESO Trial at ASCO
Adaptimmune is set to unveil crucial findings from the planned interim analysis of its IGNYTE-ESO Trial at the upcoming ASCO event. The data underscores the positive impact of Lete-cel in advancing the treatment of sarcoma, supporting continued growth within the franchise.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.